AltheaDx Receives CLIA Certification
Main Category: Pharma Industry / Biotech IndustryArticle Date: 27 May 2009 - 1:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
AltheaDx, a world leader in the development of companion diagnostics and biopharma services, announced that they have successfully passed the State of California survey for CLIA (Clinical Laboratory Improvement Amendments) certification. AltheaDx is offering high-quality patient and biopharma molecular testing services from their state-of-the-art, GMP, GLP, and now CLIA compliant facility located in the Sorrento Valley, San Diego.
"We are excited about the addition of clinical laboratory testing to the suite of services in our offering," said David Macdonald, CEO of AltheaDx. "We are now able to extend our success into later stage clinical trials and provide broader market access for our assays. Our CLIA certification is an important milestone in realizing our strategy of bringing theranostics into clinical use."
AltheaDx provides its customers with a full range of molecular biopharma services: from biomarker discovery, clinical studies, diagnostic translation, through to reporting clinical results. AltheaDx will immediately provide clinical genotyping services from their CLIA certified laboratory for the K-RAS gene, along with a menu of other high-value molecular tests.
K-RAS testing allows clinicians to screen patients for mutations in the K-RAS gene, which are found in 35-45% of metastatic colorectal cancer cases as well as a variety of other cancers including breast, lung, and ovarian. K-RAS mutations have been shown to be predictive of limited clinical response and poor prognosis. Data announced at last year's ASCO conference has led to a need for colorectal cancer patients to be screened for mutations in the K-RAS gene in order to identify the most appropriate therapy. Patients carrying mutations in the K-RAS gene do not respond to a class of drugs known as EGFR inhibitors -- such as Vectibix® and Erbitux®.
Source
AltheaDx
Visit our pharma industry / biotech industry section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/151426.php>
APA
http://www.medicalnewstoday.com/releases/151426.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



